Results of the 2016 Annual General Meeting
April 28, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that, at its Annual General Meeting held at The Merrion Hotel, Upper Merrion
Street, Dublin 2, Ireland at 11.30am today, all resolutions contained in the
Notice of Meeting were decided by poll vote. The results of the poll are as
follows:
Resolutions For % Against % Votes Withheld
(including cast as a
discretionary % of
votes) relevant
shares in
issue
Ordinary Resolutions
1. To receive the 470,025,424 98.71% 6,142,245 1.29% 80.26% 291,113
Company's Annual Report
and Accounts for the year
ended December 31, 2015.
2. To approve the 235,249,661 50.55% 230,154,350 49.45% 78.45% 11,054,771
Directors' Remuneration
Report.
3. To re-elect Dominic 470,121,989 98.70% 6,207,408 1.30% 80.29% 129,385
Blakemore as a Director.
4. To elect Olivier 466,427,485 97.92% 9,905,128 2.08% 80.29% 126,169
Bohuon as a Director.
5. To re-elect William 470,549,161 98.79% 5,783,700 1.21% 80.29% 125,921
Burns as a Director.
6. To re-elect Dr. Steven 468,848,644 98.43% 7,483,905 1.57% 80.29% 126,233
Gillis as a Director.
7. To re-elect Dr. David 474,415,296 99.60% 1,917,736 0.40% 80.29% 125,750
Ginsburg as a Director.
8. To re-elect Susan 463,855,077 97.38% 12,478,702 2.62% 80.29% 125,003
Kilsby as a Director.
9. To elect Sara Mathew 469,790,821 98.63% 6,542,652 1.37% 80.29% 125,309
as a Director.
10. To re-elect Anne 466,021,105 98.89% 5,252,483 1.11% 79.44% 5,185,194
Minto as a Director.
11. To re-elect Dr. 474,415,807 99.60% 1,919,364 0.40% 80.29% 123,611
Flemming Ornskov as a
Director.
12. To elect Jeffrey 470,866,225 98.85% 5,468,257 1.15% 80.29% 124,300
Poulton as a Director.
13. To re-appoint 454,250,728 96.38% 17,054,940 3.62% 79.44% 5,153,114
Deloitte LLP as the
Company's Auditor.
14. To authorize the 462,464,490 97.53% 11,710,617 2.47% 79.93% 2,283,675
Audit, Compliance & Risk
Committee to determine
the remuneration of the
Auditor.
15. To authorize the 440,997,344 92.79% 34,255,367 7.21% 80.11% 1,206,071
allotment of shares.
Special Resolutions
16. To authorize the 446,395,797 94.39% 26,542,021 5.61% 79.72% 3,520,964
disapplication of
pre-emption rights.
17. To authorize 470,214,310 98.72% 6,115,636 1.28% 80.29% 128,836
purchases of own shares.
18. To increase the 465,305,718 97.69% 11,024,146 2.31% 80.29% 128,918
authorized share capital.
19. To adopt new Articles 451,403,800 97.16% 13,173,422 2.84% 78.31% 11,881,560
of Association.
20. To approve the notice 429,265,355 90.61% 44,462,801 9.39% 79.85% 2,730,626
period for general
meetings.
The Board is pleased to have secured the support of our shareholders for all
resolutions. We have engaged extensively with our major shareholders on the
remuneration report and acknowledge the vote today. We remain firmly committed
to a constructive and appropriate dialogue to fully understand shareholder
views as we compete in a global market place.
As at the record date, April 26, 2016, the Company had 593,249,631 Ordinary
Shares of 5 pence each in issue (excluding shares held in treasury).
Shareholders are entitled to one vote per share. A vote "withheld" is not a
vote in law and is not counted in the calculation of the proportion of votes
validly cast.
In accordance with Listing Rule 9.6.2R copies of the relevant resolutions
passed at the meeting have been submitted to the National Storage Mechanism and
will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Sarah Elton-Farr seltonfarr@shire.com +44 1256 894157
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.
www.shire.com